Lindahl advises Senzime AB on a directed new share issue of SEK 100 million
Lindahl has advised Senzime AB (publ) in connection with a directed new share issue that will provide the company with SEK 100 million before transaction costs.
The subscription price was determined through an accelerated bookbuilding process, with Carnegie Investment Bank acting as financial adviser.
About Senzime
Senzime AB is a company listed on Nasdaq Stockholm that develops and markets CE and FDA approved monitoring systems for patients undergoing anaesthesia.
Lindahl's team consisted of Mattias Prage, Andreas Mellberg and Michaela Larsson.
Do you want to know more? Contact:
Mattias Prage
Partner | AdvokatMichaela Larsson
Associate | AdvokatAndreas Mellberg
Counsel | AdvokatCarousel items
-
News articles
6/25/2026
Lindahl recognised in IP Stars 2026
Lindahl advances to Tier 2 in Copyright & related rights in IP Stars 2026, retains strong rankings in trade mark law, and sees several lawyers recognised with individual awards.
-
Cases and transactions
6/23/2026
Lindahl acts as legal adviser to Medivir in a private placement of approximately 140 MSEK
Lindahl acted as legal adviser to Medivir in connection with an oversubscribed private placement of SEK 140 million for the clinical development of the drug candidate MIV-711.
-
Knowledge
6/15/2026
Properly prepared — contract law in the new security landscape
Preparedness laws such as the Rationing Act and the Requisition Act can alter your contracts from one day to the next. Lindahl cuts through the terminology in the new security landscape.
-
Portraits
6/2/2026
Björn on M&A at Lindahl: "No two deals are alike"
Björn Andersson on M&A at Lindahl: how each transaction brings new challenges – and why no two deals are alike. Read about his experience and approach.
-
Read more news and insights?
